Business Wire

New Study Demonstrates Zephyr Endobronchial Valves Significantly Improve Breathing, Mobility and Quality of Life for Emphysema Patients

Del

Pulmonx® Corp. today announced the publication of positive six-month results from TRANSFORM, a multicenter, multinational, randomized clinical trial (RCT) of the Zephyr® Endobronchial Valve (EBV®) in The American Journal of Respiratory and Critical Care Medicine.

According to the authors, Zephyr EBV treatment “results in clinically meaningful and statistically significant benefits in lung function, dyspnea, exercise tolerance and quality of life over current standard of care medical therapy” when used in heterogeneous emphysema patients with hyperinflation and no collateral ventilation in the target lung lobe.

The authors conclude that, “Benefits are in line with those seen with LVRS (lung volume reduction surgery), and the consistent trial results, potential reduction in post-procedure morbidity, and reversibility of the procedure position Zephyr EBV as a viable treatment option in those who remain symptomatic on maximal medical therapy.”

The TRANSFORM trial was conducted at 17 centers in six European countries and enrolled 97 patients with heterogeneous emphysema and no collateral ventilation in the target lobe, as determined by the company’s Chartis® System. Patients were randomized 2:1 to Zephyr EBV treatment versus optimal medical therapy.

The study met its primary endpoint, with 67 percent of patients having a 12 percent or greater improvement in lung function (FEV1) at three months in the per protocol group, compared to seven percent in the control group. In the intention-to-treat population at six months, Zephyr EBV patients experienced clinically and statistically greater improvements over the control group across multiple outcome measures, including lung function (29.3 percent increase in FEV1), exercise capacity (78.7m increase in 6MWD), and quality of life (6.5 point decrease in SGRQ score). A majority of EBV patients had an improvement of one or more points in the BODE index, an aggregate measure of health status, which has been associated with a significant decrease in mortality in this population.

Patients in the control arm were allowed to cross over to Zephyr EBV treatment at six months, if desired; 94 percent of control patients opted for Zephyr treatment following their assessments at six months.

The most common serious adverse event seen in the trial was a pneumothorax, which occurred in 29 percent of patients. For comparison, 90 percent of lung volume reduction surgery patients, and four to 42 percent of patients undergoing CT-guided biopsy, experience such events. The study authors noted that the occurrence of pneumothorax does not appear to negatively impact clinical outcomes.

“Zephyr EBV treatment delivers benefits similar to those seen with surgery, with the added benefit of being suitable for a broader range of patients,” said lead author, Dr. Samuel Kemp of the Royal Brompton Hospital in London, England.

Zephyr Endobronchial Valves are tiny, minimally-invasive, one-way valves placed via a flexible bronchoscope in airways of the lungs to occlude diseased regions and reduce lung hyperinflation. As a result, the remaining healthier regions can function more efficiently, enabling better breathing and an improved quality of life for patients.

“This was one of the most rigorous studies of the Zephyr EBV done to date in emphysema patients with heterogeneous emphysema and one or more lobes without collateral ventilation,” said Pulmonx Chief Executive Officer Glen French. “TRANSFORM shows definitive evidence of the tremendous benefit our technology can bring to patients who otherwise suffer from difficult breathing and are at high risk of morbidity and mortality. It is gratifying to be able to bring new hope to this underserved patient group.”

Over the past 10 years, approximately 50,000 Zephyr EBVs have been implanted globally in more than 12,000 patients. To view a video of the Zephyr EBV procedure, click here.

About Pulmonx

Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com.

The Zephyr Endobronchial Valve is an investigational device in the United States. Limited by U.S. law to investigational use only.

Contact information

Chronic Communications
Michelle McAdam
+1 (949) 545 6654 or +1 (310) 902 1274
michelle@chronic-comm.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Planview Empowers Organizations to Realize Agile-at-Scale with Lean and Agile Delivery Solution18.2.2019 15:05:00Pressemelding

Today’s increasingly competitive and disrupted markets require teams and enterprises to adapt quickly and speed delivery of innovative products, solutions, and customer experiences. While agile ways of working have produced positive results on single teams, leveraging Agile across the organization creates a challenge – how to scale delivery across teams for larger initiatives and focus on business outcomes for driving change and results. The Planview® solution for Lean and Agile delivery solves this challenge by connecting agile delivery with strategic planning and lean portfolio management to achieve business objectives faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005030/en/ The Planview solution for Lean and Agile delivery connects strategic planning, lean portfolio management, and work delivery. (Graphic: Business Wire) “When Planview came together with LeanKit® in December 2017, we significantly expanded

The University of Luxembourg Launches a Unique Interdisciplinary Space Master in Line with the Government’s SpaceResources.lu Initiative18.2.2019 14:07:00Pressemelding

In fall 2019, the University of Luxembourg launches a two-year Interdisciplinary Space Master program. This Master study program, set up in collaboration with the Luxembourg Space Agency, aims to provide students with the engineering skills required in the burgeoning space industry, along with in depth knowledge to manage space-related business activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005215/en/ Etienne Schneider, Deputy Prime Minister and Minister of the Economy ; Stéphane Pallage, Rector of the University of Luxembourg ; Claude Meisch, Minister for Higher Education and Research © University of Luxembourg (Photo: Business Wire) In 1985, a public-private partnership effort launched Société Européenne des Satellites, today known as global satellite operator SES. Over the last decades, further space-related services and businesses have developed alongside SES shaping a vibrant space economy. As a leader

Wipro Launches QuMiC to Accelerate Migration to Oracle Cloud18.2.2019 13:55:00Pressemelding

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the launch of QuMiC (Quick Migration to Cloud), a comprehensive platform designed to transform the way organizations migrate to Oracle Cloud. Using QuMiC, Wipro and Oracle aim to simplify and accelerate the journey to Oracle Cloud for their customers. Wipro is a Platinum level member of Oracle PartnerNetwork (OPN). Wipro’s QuMiC is a unique platform that migrates all aspects required for a cloud implementation, i.e. process definitions, configurations, data, and code to Oracle Cloud for a wide variety of software environments. Irrespective of whether an organization’s original assets are in an on-premise platform such as Oracle E-Business Suite, a version management tool, or another cloud software-as-a-service (SaaS) environment, QuMiC can automate and thereby, seamlessly accelerate the migration process. The platform reduces the

Top Mobility Firms Combine to Form Sterling Lexicon18.2.2019 13:47:00Pressemelding

Two of the mobility industry’s most trusted leaders – Lexicon Relocation and Sterling Mobility – this week announced the launch of their new brand, Sterling Lexicon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005205/en/ In mid-2018, Lexicon Relocation acquired Sterling Mobility, expanding their combined global footprint and service offerings in the mobility marketplace. After six months of integration, the companies have rolled out as one unified, global brand. The integration of the two companies enables Sterling Lexicon to deliver end-to-end services around the world. Focused on personalized, high-touch and quality solutions, Sterling Lexicon’s global employees expertly manage any relocation needs for private and corporate customers. “Individually, Lexicon and Sterling were highly regarded in the relocation industry, with a reputation for outstanding customer service. Together, we bring an unparalleled level of c

Milrem Robotics’ THeMIS UGV Strengthens Its Position as The Industry Standard18.2.2019 13:00:00Pressemelding

The unmanned warfare systems developer Milrem Robotics is the most represented company in its field at this year’s IDEX with the widest selection of different weaponized unmanned ground systems on display. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005105/en/ Together with industry partners MBDA, Electro Optic Systems, ST Engineering and Nexter, Milrem Robotics is exhibiting four different weaponized unmanned ground systems at the main defence event in the Middle East. All systems are integrated onto Milrem Robotics' THeMIS unmanned ground vehicle. (Photo: Business Wire) Together with industry partners MBDA, Electro Optic Systems, ST Engineering and Nexter, Milrem Robotics is exhibiting four different weaponized unmanned ground systems at the main defence event in the Middle East. All systems are integrated onto Milrem Robotics’ THeMIS unmanned ground vehicle. On display are two completely new weaponized UGVs – the

Saudi Arabia Ministry of Health and Masimo Announce Automation of National Neonatal CCHD Screening Process Using Masimo Technology18.2.2019 13:00:00Pressemelding

Recently at Arab Health 2019, the Saudi Arabia Ministry of Health (MOH) and Masimo (NASDAQ: MASI) jointly announced the implementation of an automation solution designed to streamline the process of critical congenital heart disease (CCHD) screening of newborns using Masimo SET®, the first automation of its kind worldwide. This latest phase in Saudi Arabia’s national CCHD screening program, which began in 2016 as part of the Vision 2030 plan addressing improvements in healthcare and other areas, automates the collection and storage of screening data, helping to make the process both more efficient and more accurate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005021/en/ Masimo Rad-97™ with Eve™ (Photo: Business Wire) In 2016, Saudi Arabia implemented a mandatory CCHD screening program for all newborns using the Masimo Eve™ Newborn Screening Application on Radical-7® Pulse CO-Oximeters® with SET® Measure-through Moti